Semaglutide / Tirzepatide
Prescription medications a physician may consider for weight management after a clinical evaluation. Compounded preparations are not FDA-approved, and the FDA has not reviewed them for safety, effectiveness, or quality.
Compounded medications are not FDA-approved and are not the same as brand-name products.
Mechanism of action
How Semaglutide / Tirzepatide works
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a GIP and GLP-1 receptor agonist. Your physician reviews your history, weight, and labs, then decides whether a medication in this class is appropriate and whether an FDA-approved product or a patient-specific compounded preparation meets your clinical needs. Studies of FDA-approved medicines were not conducted on compounded preparations and do not establish how a compounded preparation will perform.
Areas of study
What Semaglutide / Tirzepatide is studied for
- check
Physician-supervised weight management for adults who meet clinical criteria
- check
Compounded preparations themselves have not been evaluated in clinical trials reviewed by the FDA
Considerations
Important things your physician will discuss
This is general clinical context — not medical advice. Your evaluation determines whether Semaglutide / Tirzepatide is appropriate for you.
- info
Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN-2
- info
GI side effects (nausea, transient appetite suppression) are common during titration
- info
Not appropriate during pregnancy, breastfeeding, or planned conception
- info
A compounded preparation is prescribed only when your physician documents a clinical need that an FDA-approved product does not meet
- info
Compounded medications are not generics and are not the same as FDA-approved drugs
Used in
Protocols that reference Semaglutide / Tirzepatide
Curious whether this peptide fits your protocol?
A licensed Allora physician will review your goals, history, and labs before recommending any therapy.